Scrip | What Does 2022 Hold For Biopharma?
Feb 2022
Originally published by SCRIP on February 8 , 2022.
James West, Director in Lincoln’s Healthcare Group shares that there has been increased private equity firm’s interest in the Biopharma space and expects continued activity in this sphere for the year 2022 .
Summary
-
James West, Director at Lincoln International's Healthcare Group speaks with Scrip on Biopharma market and trends for 2022.
- Sign up to receive Lincoln's perspectives
Contributor
Related Perspectives
HealthInvestor | CMA Launches Review of Vet Sector
Originally posted by HealthInvestor on September 7, 2023. The Competition and Markets Authority (CMA) has begun reviewing UK veterinary services to uncover how well the market is working for pet… Read More
Conceiving Success: Growth and Consolidation in IVF in APAC and the Middle East
In-vitro fertilization in Asia-Pacific and the Middle East is growing quickly due to several factors; the industry’s rapid growth offers an opportunity for investors to capitalize on momentum. In a… Read More
No Surprises Act Changes U.S. Healthcare System
The implementation of the No Surprises Act (NSA)’s out-of-network (OON) billing restrictions, coupled with its disclosure and transparency requirements, has resulted in significant changes to healthcare financing and consumption across… Read More
Lincoln’s Latest
Lincoln’s Latest video series features experts from across industries, services and geographies, sharing perspectives on current trends, recent observations and future outlooks.
